Journal
Noom Med Review 2026: A Microdose GLP-1 Program Attached to the Famous App
Released: Last reviewed:
Short answer — August 2026
Noom Med pairs compounded GLP-1 medication with the curriculum-driven behavior app Noom built its name on. On our August 2026 record that meant compounded semaglutide at one ninety-nine a month and no tirzepatide; on October 15, 2026 Noom's page described a microdose semaglutide and tirzepatide program at $79 for the first period, then $179 a month on a 12-week subscription. Microdosing means lower-than-standard doses, which no trial has shown to produce the same results; the price difference partly reflects the app-plus-coaching layer. The review is therefore the familiar test with a specific twist: behavior-change support is exactly what the regain data says the medication era undervalues — if it gets used, and if this implementation of it suits you.
The psychology-plus-pharmacology case, and verdict
The honest strengths: Noom's structured curriculum, logging, and coaching attack the maintenance problem the vial can't — the habits that decide what happens after the losing phase — and bundling them with the prescription puts the two halves of treatment in one subscription. The honest limits: the app model predates the GLP-1 era and reviews of it vary widely by user temperament (curriculum-lovers thrive; notification-fatigued churn); the seventy-dollar spread to the floor buys it whether used or not; tirzepatide appears only inside the microdose program, with no separate price printed on the page we read; and the pharmacy behind the prescription is the standard unnamed-until-asked. Fit: a semaglutide buyer who genuinely wants structured behavioral scaffolding and knows their own compliance with app-based programs — for whom one ninety-nine is a fair two-in-one. Anti-fit: anyone who'd let the app rot while paying its premium, for whom bmiMD's one twenty-nine plus a free habit of choice is the same treatment at the honest price.
Questions people ask
How much is Noom Med?
On October 15, 2026, Noom's page listed its microdose compounded semaglutide program at $79 plus tax for an initial 3-week subscription with 4 weeks of medication, then $179 a month plus tax on a 12-week subscription. Our August 2026 record had $199 a month for compounded semaglutide. The program bundles Noom's behavior-change app and coaching.
Is Noom Med worth more than lower-priced semaglutide programs?
If you'll use the curriculum, plausibly: structured behavioral support targets exactly the maintenance problem the regain trials expose. If app-based programs historically rot on your phone, the premium buys shelf-ware. Also note Noom's current program is a microdose program, not a standard-dose one.
Does Noom Med offer tirzepatide?
Noom's page, read on October 15, 2026, describes its program as "Microdose Compounded Semaglutide and Tirzepatide," but it printed no separate tirzepatide price. A microdose program uses lower-than-standard doses; tirzepatide shoppers who want a standard-dose price should compare programs that print one, with behavioral support added separately if wanted.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.